Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers found that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer. Aromatase inhibitors, which block the production of estrogen, were shown to be effective in reducing tumor size and improving surgical outcomes.
A new study found that most blacks who don't call emergency services for stroke symptoms believe their symptoms are not serious enough or will resolve on their own. The survey suggests that education campaigns need to emphasize the importance of timely treatment and calling 911 immediately.
Researchers found that celecoxib induced an anti-tumor response at the molecular level, affecting genes involved in cell proliferation, apoptosis, and extracellular matrix biology. The study suggests that celecoxib may be efficient as a cancer treatment for people with primary invasive breast cancer.
Researchers discover natural compound acetyl resveratrol protects mice from radiation damage, potentially overcoming existing drug's limitations. The substance can be easily produced in large quantities and administered orally.
Researchers at Georgetown University Medical Center report that a drug developed to treat Ewing's Sarcoma may also prevent human prostate cancer from spreading. The agent, YK-4 279, was found to inhibit functions of proteins responsible for aggressive cell behavior in prostate cancer cells.
A novel potential drug-target for colorectal cancer treatment has been identified in a brain-derived protein. Brain-derived neurotrophic factor (BDNF) is present in greater amounts in colorectal tumors and may be involved in CRC progression and resistance to drugs.
A clinical trial at UT Southwestern Medical Center found that a biweekly dose of dactinomycin had a higher complete response rate than a weekly dose of methotrexate for treating low-risk gestational trophoblastic neoplasia. This regimen also required fewer treatment cycles and had lower toxicity.
A phase II study of selumetinib has shown promising results in patients with advanced biliary cancer, with significant tumor shrinkage and weight gain observed. The drug blocked the MEK protein, which is often damaged in biliary cancer cells, suggesting a new standard of care may be established
Researchers at U-M Comprehensive Cancer Center found that PARP inhibitors, currently used for breast and ovarian cancers, can also work against colorectal tumors with MRE11 gene mutations. The study suggests targeting these patients specifically could be a new therapeutic approach.
A Phase 3 clinical trial found that adding atrasentan to chemotherapy did not improve survival for patients with advanced prostate cancer. Patients who received the drug had similar progression-free survival as those given a placebo.
Researchers at Stanford University have developed a new biosensor microchip that can analyze thousands of protein-binding events simultaneously and continuously, potentially speeding up the process of drug development. The technology uses magnetic nanotags to detect interactions with greater sensitivity, enabling researchers to predict...
Researchers at UC San Diego School of Medicine have discovered a potential cancer biomarker in non-human sialic acid antibodies, which can also be used as a treatment to suppress tumor growth. The study found that patients with carcinomas have elevated levels of antibodies to one specific Neu5Gc-containing sugar chain.
A biophysicist is developing a drug that targets Interleukin-6 (IL-6) to combat breast and prostate cancer. By blocking the protein's signaling pathway, researchers aim to prevent cellular inflammation and tumor growth.
A study by UCLA researchers found that ACE inhibitors may increase the risk of breast cancer recurrence in women who have had early-stage breast cancer. In contrast, beta blockers appeared to have a protective effect, and when used together with ACE inhibitors, may help mitigate this risk.
Researchers at Columbia University Irving Medical Center have developed an innovative yeast-based screening method to identify a possible new treatment for the fatal childhood disease NP-C. The approach, known as 'exacerbate-reverse', has shown promising results in repairing genetic pathways that exacerbate lethality in yeast models.
A new study by Ohio State University researchers shows that chronic inflammation can lead to cancer by stimulating the production of microRNA-155, which increases the rate of spontaneous gene mutations. This discovery suggests that reducing miR-155 levels may improve treatment for inflammation-related cancers.
Breast cancer patients whose cells use ketones and lactate as a food supply can be identified by gene profiling, predicting recurrence, metastasis, and poor clinical outcome. The researchers propose using this approach, called Metabolo-Genomics, to target oxidative mitochondrial metabolism with new anti-cancer drugs.
An experimental drug called NVP-BEZ235 blocks a crucial cancer cell signaling pathway, slowing ovarian cancer growth and increasing survival in an ovarian cancer mouse model. The drug also re-sensitizes resistant cancer cells to platinum chemotherapy, offering new hope for fighting drug resistance.
A study by University of Pennsylvania School of Medicine investigators shows that mice lacking a key protein develop squamous cell cancers resembling human disease, supporting novel therapies and early detection strategies. The findings settle a 20-year debate and prove the protein's role as a tumor-suppressor.
The National Institutes of Health has funded a study to develop an inhaled lung cancer treatment using the drug 5-azacytidine. Researchers at Albert Einstein College of Medicine aim to target premalignant lung cancer by reactivating genes that suppress tumors.
Researchers at NYU School of Medicine identified three novel small molecules that block a crucial cellular communication pathway regulating cancer growth. The finding could provide the basis for innovative therapies for colorectal cancer and other diseases associated with aberrations in this pathway.
Researchers discovered Camel-raised Nanobody agents that target breast cancer cells, offering a new approach to identifying effective treatments for individual patients. The 'Nanobodies' are robust, small, and easy to produce at low cost, making them a promising tool in the fight against breast cancer.
A new drug, DCC-2036, has shown potential in treating leukemia patients who have developed resistance to standard treatment. The study found that the drug was effective against human leukemia cells and prolonged survival in a mouse model of CML.
A newly discovered hybrid gene is found to play a role in some stomach cancers, potentially fueling tumor growth and survival. The CD44-SLC1A2 fusion gene may be at work in up to 2 percent of stomach cancers and could lead to improved therapies.
Researchers developed small-molecule MDM2 inhibitors that activate p53 protein, killing cancer cells while avoiding DNA damage. These new drugs shrank tumors in animal models of human cancer without significant side effects.
Researchers from UPCI and Pitt will present over 80 posters, talks, and tutorials on various cancer studies, including the effects of immunomodulatory derivatives on blood cell production pathways and the role of inflammatory mediators in immune system dysfunction. Additionally, they will discuss the development of vaccines targeting p...
A Purdue University biochemist has created a nanopolymer that can be coated with drugs and then removed to determine which proteins the drug has entered. This development may help reduce side effects associated with cancer drugs by allowing for more targeted drug delivery.
Researchers at Fox Chase Cancer Center have developed a screen to identify proteins that work with histone deacetylases and DNA methyltransferases to repress gene expression. The method revealed 128 factors involved in regulating gene expression, potentially leading to broader cancer therapies
Researchers at the University of Pennsylvania School of Medicine have found a novel drug combination that successfully treats advanced cancer patients. The temsirolimus-hydroxychloroquine combination was shown to halt tumor growth in two-thirds of patients, including those with melanoma, colorectal, and head and neck cancers.
Researchers at Queen's University Belfast have developed a new drug that prevents tumor growth by cutting off their blood supply, showing promise for treating prostate and breast cancers. The treatment targets tumor angiogenesis using an entirely different pathway than existing therapies.
Researchers found that men using digoxin had a 24% lower risk of prostate cancer. The study also identified other approved drugs with anti-prostate cancer properties, paving the way for further research and potential new treatments.
Researchers sequenced whole genomes of tumors from 50 breast cancer patients and compared them to healthy cells, finding over 1,700 unique mutations. The study highlights the complexity of cancer genomes and offers new insights into personalized medicine.
The American Association for Cancer Research is prioritizing clinical trials to advance cancer treatment and prevention. Researchers presented findings on basal cell cancer and lung cancer, highlighting the potential of biomarkers and hedgehog pathway inhibitors. New discoveries aim to improve patient outcomes and reduce side effects.
PBS-Bio presents two abstracts at the AACR conference, showing how drugs UNBS1450 and NDC-1308 affect cancer cells. The technology allows real-time measurement of cellular responses to drugs, identifying potential biomarkers for patient selection and drug development.
Researchers will study how tumor cells avoid immune detection, enabling cancer spread, and test whether modifying the environment can activate unresponsive immune cells against cancer. The grant enables visualization of tumor and immune cell interactions in real-time.
A new therapeutic target for lung cancer has been identified by researchers at Seoul National University. The variant of the protein AIMP2 is highly expressed in lung cancer cells and has been shown to compromise the tumor-suppressing activity of AIMP2, suggesting its potential as a new treatment option.
Researchers at the University of Michigan have developed a new drug called AT-406 that effectively targets proteins blocking normal cell death, leading to tumor cell death while sparing normal cells. The drug has shown promising results in animal models, shrinking tumors with minimal side effects.
Researchers develop innovative strategy to target tumor metabolism, block energy production required for malignant cancer growth, delaying tumor volume and spread. The treatment combines ultrasound-guided intra-tumoral delivery of a potent drug with imaging guidance to minimize healthy tissue exposure.
A new nanodrug breaks down barriers to attack breast cancer cells by carrying multiple drugs that accumulate in tumor cells and strike cancer-specific molecular targets. This targeted approach shows promise as a more effective treatment method than standard treatment, with the potential to be tailored for various disorders.
Scientists have discovered stapled peptides that can target proteins involved in colon cancer and asthma. These peptides, which are not small molecules, inhibit activity of key proteins in the body, offering a new frontier in medicine.
A Phase II trial of Gleevec (imatinib) has shown acceptable safety and tolerability, with hints of efficacy in treating diffuse scleroderma. The drug improved skin scores by 22% and forced vital capacity scores by 6.4% after 12 months of therapy.
The American Association for Cancer Research (AACR) is honoring two renowned cancer researchers, Helen Blau and Nathanael Gray, for their groundbreaking contributions to the field. Helen Blau's work on regenerative medicine and cellular plasticity has led to new approaches in modeling diseases and regenerating damaged tissues.
The FDA is considering new rules to speed up confirmatory trials of drugs granted accelerated approval, following a review that found six indications remained on the market without confirmation. The median time between accelerated and regular approval was 3.9 years, with some drugs remaining on the market for over 10 years.
The American Association for Cancer Research and the Landon Foundation will present three INNOVATOR Awards to recognize emerging mid-career researchers. The awards support innovation in cancer prevention, international collaboration, and personalized medicine research.
Susan Band Horwitz, a renowned molecular pharmacologist, receives the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Her pioneering work on paclitaxel has led to significant advancements in cancer treatment, particularly in ovarian, breast, and lung carcinomas.
Pier Paolo Pandolfi has made significant contributions to cancer research, particularly in the area of leukemia treatment. His work on mouse models and chromosomal translocations has led to the development of novel therapeutic strategies, making APL a curable disease.
Researchers at UCLA developed a 'roadmap' of complex signaling processes in cancer that could lead to new methods for diagnosing and overcoming drug resistance. The study identifies points of susceptibility that can be targeted by 'cocktail' therapies to prevent drug resistance.
Researchers discover PinX1's role in preventing chromosome instability and cancer initiation. Low levels of PinX1 contribute to cancer development by activating telomerase, a process linked to human cancers with genetic alterations at chromosome 8p23.
A new oral drug intended to protect healthy tissue from radiation effects has been found safe for use in advanced non-small cell lung cancer patients. The agent, called manganese superoxide dismutase plasmid liposome, boosted antioxidant levels and reduced inflammation without protecting tumor cells.
A new clinical trial, sponsored by the National Cancer Institute, is testing whether rosuvastatin reduces the risk of recurrent colon cancer. The five-year study involves 1,740 patients and will determine if statins are effective in preventing colon cancer.
Scientists at Notre Dame and Cornell have made a breakthrough in understanding the genetic disorder Niemann-Pick Type C, which affects brain cells and causes devastating symptoms. Using histone deacetylase inhibitors, researchers were able to correct the damage done by the genetic flaw and restore normal cell function.
A study by Albert Einstein College of Medicine researchers found that an enzyme family, katanin, regulates cell motility. Treating this enzyme can encourage cells to migrate in a particular direction to heal wounds. This discovery could lead to new therapeutic agents for conditions like diabetic ulcers and metastatic cancer.
A Purdue University scientist has developed a nanopolymer that can detect the effectiveness of cancer drugs against biochemical processes leading to cancer cell formation. This innovation could replace radioisotopes and antibodies in screening kinase inhibitors, making it a universal method for pharmaceuticals.
Measuring mechanical strength of cancer cell mucus layers provides clues about treating cancer. Cancer cells produce excessive mucus, forming a barrier that prevents drugs from reaching them.
A new study sponsored by the National Heart, Lung, and Blood Institute found that sirolimus therapy can improve lung function and quality of life in individuals with lymphangioleiomyomatosis (LAM). The treatment was shown to slow disease progression and improve clinical outcomes in patients with this rare and progressive lung disease.
Research findings challenge traditional views on cancer treatment, revealing Cop1's role in tumor suppression rather than promotion. The study suggests that inhibiting Cop1 could stimulate cell proliferation in cancer cells.
Researchers at Dana-Farber Cancer Institute have found that a malaria drug, hydroxychloroquine, can slow the growth of pancreatic tumors in mice. The oral drug has been shown to decrease tumor growth by inhibiting autophagy, a survival strategy used by cancer cells.
A study published in Cancer suggests that tamoxifen can significantly reduce breast cancer risk in post-menopausal women under 55 with a high risk of developing the disease. The medication not only saves lives but also reduces medical costs, preventing 29 breast cancer cases and 9 deaths per 1,000 treated women.
A new treatment strategy using chemotherapy drugs Erlotinib and Gefitinib has been found to be effective in treating a subset of patients with advanced non-small-cell lung cancer. The drugs, which target the EGFR mutation, produced a response rate of over 70% and had fewer side effects compared to traditional treatments.
A Northwestern University research team found that binding chemotherapy drugs to nanodiamonds significantly improves the effectiveness of cancer treatment, particularly in cases where tumors are resistant to conventional therapies. The discovery holds promise for treating aggressive cancers with fewer toxic side effects.